Slovenia follows with 21.7% of cancer spending on prescribed medicines in 2006, and Korea with 12.6% of cancer care spending on prescribed drugs and 2.9% on over-the-counter medicines in 2005. They were also authorised rapidly in Switzerland, Chile, Sweden and France. For example, in the United States and Switzerland, seven out of the ten drugs were authorised before the year 2000. Some countries such as Japan, Norway and Hirkey were initially slow in authorising these drugs but caught up with the others by 2010, authorising all ten drugs.